Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease

被引：0
|
作者：
Anna Juncadella
Konstantinos Papamichael
Byron P. Vaughn
Adam S. Cheifetz
机构：
[1] Harvard Medical School,Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth
[2] University of Minnesota,Israel Deaconess Medical Center
来源：
Digestive Diseases and Sciences | 2018年 / 63卷
关键词：
Anti-TNF therapy; Crohn’s disease; Ulcerative colitis; Antibodies to adalimumab; Therapeutic drug monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3067 / 3073
页数：6
相关论文
共 50 条
  • [1] Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease
    Juncadella, Anna
    Papamichael, Konstantinos
    Vaughn, Byron P.
    Cheifetz, Adam S.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (11) : 3067 - 3073
  • [2] Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
    Wong, Rochelle
    Qin, Lihui
    Pan, Yushan
    Mahtani, Prerna
    Longman, Randy
    Lukin, Dana
    Scherl, Ellen
    Battat, Robert
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [3] Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab
    Christensen, Britt
    Rubin, David T.
    Goeppinger, Sarah
    Colman, Ruben J.
    Yarur, Andres
    Hirsch, Ayal
    Bocheneck, Ashley
    Wichmann, Alana
    Sakuraba, Atsushi
    Cohen, Russell
    Siddiqui, Dania
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S783 - S784
  • [4] Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease
    Ritter, Einat
    Hirsch, Ayal
    Isakov, Naomi F.
    Ron, Yulia
    Cohen, Nathaniel A.
    Maharshak, Nitsan
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (09) : 810 - 814
  • [5] ADALIMUMAB IN THE MAINTENANCE OF REMISSION FOR INFLAMMATORY BOWEL DISEASE: NEED FOR WEIGHT-BASED DOSING?
    Chan, G.
    Martin, H.
    Farrell, R.
    [J]. GUT, 2013, 62 : A18 - A18
  • [6] Serum levels of infliximab and adalimumab are associated with deep remission in inflammatory bowel disease
    Pascual-Marmaneu, Oscar
    Belles-Medall, Maria D.
    Ferrando-Piqueres, Raul
    Almela-Notari, Pedro
    Mendoza-Aguilera, Maria
    Alvarez-Martin, Tamara
    [J]. FARMACIA HOSPITALARIA, 2021, 45 (05) : 225 - 233
  • [7] High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
    Aze Wilson
    Bethany Choi
    Michael Sey
    Terry Ponich
    Melanie Beaton
    Richard B. Kim
    [J]. BMC Gastroenterology, 21
  • [8] High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
    Wilson, Aze
    Choi, Bethany
    Sey, Michael
    Ponich, Terry
    Beaton, Melanie
    Kim, Richard B.
    [J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [9] Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease
    Papamichael, Konstantinos
    Rakowsky, Shana
    Rivera, Claudio
    Cheifetz, Adam S.
    Osterman, Mark T.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2266 - 2271
  • [10] Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
    Yarur, Andres J.
    Jain, Anjali
    Hauenstein, Scott I.
    Quintero, Maria A.
    Barkin, Jamie S.
    Deshpande, Amar R.
    Sussman, Daniel A.
    Singh, Sharat
    Abreu, Maria T.
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 (02) : 409 - 415
12345